A Review of Sirt1 and Sirt1 Modulators in Cardiovascular and Metabolic Diseases

Author: Pillarisetti, Sivaram

Source: Recent Patents on Cardiovascular Drug Discovery, Volume 3, Number 3, November 2008 , pp. 156-164(9)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

The full text is free.

View now:

PDF 272.7kb

Abstract:

Sirt1 (member of the sirtuin family) is a nicotinamide adenosine dinucleotide (NAD)-dependent deacetylase that removes acetyl groups from various proteins. A wide variety of proteins are Sirt1 substrates; the list includes many transcription factors and cofactors. Deacetylation of these factors may lead to activation or inactivation of the factor, thus impacting downstream gene expression. In addition to direct deacetylation, Sirt1 can modulate protein activity by other mechanisms. Although initial research focused on sirtuin's role in life span extension especially in lower organisms more recent studies show that Sirt1 activity can impact a wide array of proteins implicated in cardiovascular (CV) and metabolic diseases. Several patents have been published in the last 5 years describing the application of sirtuin compounds in the treatment of metabolic diseases. This review will focus on those Sirt1-modifiable proteins that have an impact on CV and metabolic diseases. Pharmacological agents that activate Sirt1 and thus impact the disease process will also be reviewed.

Keywords: Cardiovascular diseases; Sirt1; Sirt1-Activators; deacetylation; diabetes; obesity; metabolism

Document Type: Research article

Publication date: 2008-11-01

More about this publication?

Recent Patents on Cardiovascular Drug Discovery publishes review articles on recent patents in the field of cardiovascular drug discovery e.g. novel bioactive compounds, analogs & targets. A selection of important and recent patents on cardiovascular drug discovery is also included in the journal. The journal is essential reading for all researchers involved in cardiovascular drug design and discovery.